Non-Muscle Invasive Urothelial Carcinoma

Updated ENVISION Data: UGN-102 Shows 82.3% Duration of Response in LG-IR-NMIBC
Sandip Prasad, MD, MPhil, of Atlantic Health System, provides updates on the positive duration of response data observed with UGN-102 for the treatment of LG-IR-NMIBC in the ENVISION trial. ...
Advertisement

Latest News

Advertisement

Urothelial Carcinoma Knowledge Hubs

Curated clinical content based on urothelial cancer types, therapies, and technologies

Urothelial Carcinoma
Urothelial Carcinoma

Conference Coverage

Advertisement
Section Editor

Advertisement
Latest News